This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herlyn, M. Articles by Koprowski, H. Search for Related Content PubMed PubMed Citation Articles by Herlyn, M. Articles by Koprowski, H.

Specific Immunoreactivity of Hybridoma-secreted Monoclonal Anti-Melanoma Antibodies to Cultured Cells and Freshly Derived Human Cells¹

The Wistar Institute of Anatomy and Biology [M. H., Z. S., H. K.], and Pigmented Lesions Study Group, Comprehensive Cancer Center, University of Pennsylvania [W. H. C., D. G., D. E. E., D. L., R. H., E. B., R. T.], Philadelphia 19104, and American Oncologic Hospital, Fox Chase Institute [M. M.], Philadelphia, Pennsylvania 19111

The specificities of monoclonal antibodies against melanoma cells were analyzed using radioimmunoassay, mixed-hemadsorption assay, and quantitative absorption on a variety of malignant and nonmalignant cells. Three of the six hybridomasecreted antibodies bound to the majority of melanoma cell lines, melanoma tumors, and astrocytoma cell lines as well as to all normal and Epstein-Barr virus-transformed lymphocytes tested. The binding pattern coincides with the presence or absence of the DR antigen on human cells. Conversely, two other antibodies, 19-19 and Nu4B, detected two different antigens common to melanoma and astrocytoma cells only. Cloning of melanoma cells resulted in establishment of DR-positive and Dr-negative clones, with the binding of Nu4B antibody retained in all.

¹ Supported in part by Grants CA-10815, CA-21124, CA-25298, and CA-25874 from the National Cancer Institute, Grant RR-05540 from the Division of Research Resources, and funds from Pew Memorial Trust.

² To whom requests for reprints should be addressed.

Received 3/13/80. Accepted 7/11/80.

This article has been cited by other articles:

				J. Li, W. Li, S. Liang, D. Cai, M. P. Kieny, L. Jacob, A. Linnenbach, J. W. Abramczuk, H. Bender, K. Sproesser, et al. Recombinant CD63/ME491/Neuroglandular/NKI/C-3 Antigen Inhibits Growth of Established Tumors in Transgenic Mice J. Immunol., September 15, 2003; 171(6): 2922 - 2929. [Abstract] [Full Text] [PDF]

				M. Chawla-Sarkar, D. W. Leaman, B. S. Jacobs, and E. C. Borden IFN-{beta} Pretreatment Sensitizes Human Melanoma Cells to TRAIL/Apo2 Ligand-Induced Apoptosis J. Immunol., July 15, 2002; 169(2): 847 - 855. [Abstract] [Full Text] [PDF]

				M. Chawla-Sarkar, D. W. Leaman, and E. C. Borden Preferential Induction of Apoptosis by Interferon (IFN)-{beta} Compared with IFN-{{alpha}}2: Correlation with TRAIL/Apo2L Induction in Melanoma Cell Lines Clin. Cancer Res., June 1, 2001; 7(6): 1821 - 1831. [Abstract] [Full Text] [PDF]

				D Herlyn, A. Ross, and H Koprowski Anti-idiotypic antibodies bear the internal image of a human tumor antigen Science, April 4, 1986; 232(4746): 100 - 102. [Abstract] [PDF]